{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-078294","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2024-09-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.987563+00:00","generated_at":"2026-05-31T05:02:06.690241+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Allarity Therapeutics CFO resigns; appoints Alexander Epshinsky; boosts ATM capacity to $50M","bullets":["Joan Brown resigned as CFO effective Sept 12, 2024; no disagreement with company.","Alexander Epshinsky appointed CFO effective Sept 12; $340k base salary, $50k signing bonus, $160k RSUs (3-year vest).","ATM sales agreement second amendment increases placement shares capacity to $50 million.","Company states it paused financing but now, with new CFO, will pursue financing opportunities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-078294","json":"https://secwatch.observer/filing/0001213900-24-078294.json","markdown":"https://secwatch.observer/filing/0001213900-24-078294.md","text":"https://secwatch.observer/filing/0001213900-24-078294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/0001213900-24-078294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/ea0214462-8k_allarity.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T05:02:06.690241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"724ee19254","claim":"Joan Y. Brown resigned as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On September 12, 2024, the Company received a notice of resignation from Joan Y. Brown, its Chief Financial Officer, effective September 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/0001213900-24-078294-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"c3e741c96b","claim":"Alexander Epshinsky was appointed as Chief Financial Officer at Allarity Therapeutics, Inc..","evidence_excerpt":"On September 12, 2024, the Board of Directors (the “Board”) of the Company approved the appointment of Alexander Epshinsky as the Chief Financial Officer of the Company as of September 12, 2024, succeeding Ms. Brown.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1860657/000121390024078294/0001213900-24-078294-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}